Monthly Stock Report: Henry Schein, Inc. (HSIC)
Publication Date: September 22, 2024
Company Overview
Henry Schein, Inc. (HSIC) is a prominent healthcare company headquartered in Melville, New York, specializing in medical distribution. Established in 1932, the company primarily serves dental practitioners, laboratories, physician practices, and ambulatory surgery centers. Henry Schein operates through two main segments: Health Care Distribution—which encompasses an extensive range of dental and medical products including infection-control items and dental equipment—and Technology and Value-Added Services, providing software and consultancy solutions designed to enhance practice management. As a recognized stock within the healthcare sector, HSIC is positioned for investment consideration amidst the dynamic market landscape.
Current Market Analysis
The current stock recommendation for Henry Schein stands at “hold,” suggesting that existing investors should maintain their positions rather than make new investments. As of now, the market price of HSIC is $71.15, which is supported by a significant total revenue of approximately $12.49 billion. Analysts project a target high price of $83.00, indicating potential upside. The stock also sees a mean target price of $72.60, which projects modest growth. However, with approximately 5.38% of shares shorted, investor sentiment reflects a cautious outlook amidst current market dynamics.
The volatility of HSIC shares is notable, having reached a 52-week high of $82.63 and a low of $60.01. This wide range illustrates both the risks and opportunities for investors. The current price exceeds the fifty-day average of $69.78, suggesting an upward trend, although it remains approximately 13.9% below its peak. Therefore, the recommendation to “hold” aligns with the moderate performance expectations and prevailing market conditions.
Financial Performance Highlights
Henry Schein’s financial stability is highlighted by its robust total revenue of approximately $12.49 billion, emphasizing the company’s strong operational performance. However, the absence of EBITDA data limits a complete assessment of its profitability and operational efficiency, critical elements for a thorough evaluation. Notably, with 126,708,000 shares outstanding and a float of 124,998,511 shares available for trading, Henry Schein’s metrics reflect a healthy stock profile. The recommendation mean stands at 2.6 based on ten analyst opinions, showcasing a neutral sentiment toward the stock’s future trajectory.
In summary, with the current recommendation of “hold,” HSIC encapsulates a solid investment foundation within the healthcare distribution sector, providing investors with a reliable opportunity for observation and potential future engagement.
| Metric | Value |
|---|---|
| Market Cap | $9.0b |
| Total Debt | $2.8b |
| Total Cash | $138.0m |
| Shares Outstanding | 126.7m |
| Float Shares | 125.0m |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.